Sweden’s BOOST Pharma Raises €3.1M For Stem Cell Therapy For Brittle Bone Disease

The funding will advance clinical development of BT-101, its stem cell therapy for osteogenesis imperfecta (brittle bone disease).

“We are honored to welcome Sound Bioventures to our syndicate – a collaborative, hands-on investor group that shares our vision of transforming care for children living with rare skeletal diseases,” said Ingelise Saunders, Chair of BOOST Pharma. “Their commitment strengthens BOOST Pharma’s position as a leader in cell therapy for genetic bone disorders and enables continued progress of BT-101 towards the clinic.”

The investment in BOOST Pharma highlights a broader European trend in funding advanced cell and gene therapy startups in 2025. Recent examples include Sweden’s Cellcolabs (€10.3M) for stem cell manufacturing, Germany’s Akribion Therapeutics (€8M) for cell-depletion tech Finland’s StemSight (€2.3M) for vision restoration, and Denmark’s Fuse Vectors (€4.9M) for gene therapy delivery. Together these reflect Europe’s growing focus on clinical-stage biotech and regenerative medicine.

Read Also - Warsaw-Based Holi Raises €3M To Expand Its Digital Obesity Treatment Platform

“We believe BOOST Pharma’s innovative approach to treating osteogenesis imperfecta has enormous potential to deliver not only clinical impact for patients but also durable value creation. We look forward to working together to reach new milestones,” said Johan Kördel, Managing Partner at Sound Bioventures.

Founded in 2019, BOOST Pharma builds on years of research from Stockholm’s Karolinska Institute, led by associate professor Cecilia Götherström and professor Magnus Westgren, focusing on cell therapies for osteogenesis imperfecta (OI), or brittle bone disease. Their work shows that BOOST Cells can significantly improve the quality of life for patients.

The company’s lead candidate, BT-101, is a mesenchymal stem cell therapy designed for infants with OI. It aims to reduce fractures and strengthen bones by targeting the root cause early sometimes even before birth.

Preclinical and early human data show strong results: treated children experienced improved bone growth, fewer fractures, and no immune reactions. With new funding, BOOST Pharma plans to advance BT-101 through clinical development, moving closer to delivering the first disease-modifying treatment for OI.

About BOOST Pharma

BOOST Pharma, founded on pioneering research from Stockholm’s Karolinska Institute, develops novel cell therapies for osteogenesis imperfecta (brittle bone disease). Led by Cecilia Götherström and Magnus Westgren the company’s BOOST Cells have demonstrated significant improvements in bone strength and quality of life for patients with this rare genetic condition.